Psoriatic Arthritis: Biomarkers May Predict Drug Response Psoriatic Arthritis: Biomarkers May Predict Drug Response
A 1-step test of 57 synovial tissue proteins may predict which patients with psoriatic arthritis would benefit from adalimumab or abatacept. Medscape Medical News
GRAPPA and EULAR have provide updated recommendations regarding the management and treatment of psoriatic arthritis.Rheumatology
The British Association of Dermatologists provides evidence-based recommendations on the use of biologic therapies for the treatment of psoriasis and psoriatic arthritis in adults and children.The British Journal of Dermatology
Psoriatic arthritis is the second approved indication for Taltz in the United States.
AbstractSB4 [Benepali® (EU); Brenzys ™ (Australia, Canada, Korea)] is an etanercept biosimilar approved for all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. In a pha se 3 trial in patients with moderate to severe rheumatoid arthritis receiving methotrexate, the efficacy of subcutaneous SB4 was equivalent to that of reference etanercept, and both agents had a similar tolerability profile, except for a higher incidence of injection-site reactions w...
ConclusionsThe implementations of these practical recommendations could be very helpful for the management of patients with PsA in the dermatology setting including early diagnosis and treatment.This article is protected by copyright. All rights reserved.
ConclusionCZP e-Device development was guided by intended user feedback through HFS, ensuring the final design addressed patients ’ needs. In both validation studies, participants successfully performed all critical tasks, demonstrating safe and effective e-Device self-injections.FundingUCB Pharma.Plain Language SummaryPlain language summary available on the journal website.
Authors: Patience A, Helliwell PS, Siddle HJ Abstract INTRODUCTION: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis characterised by a range of musculoskeletal conditions including enthesitis, dactylitis and synovitis as well as skin and nail manifestations. The foot is a complex mixture of tissues, all of which can be involved in this disease and is frequently the presenting feature. Areas covered: In this under-researched area, articles were reviewed from the authors' publications as well as from other known authors. This review will discuss how PsA affects the foot and ankle with a pa...
ConclusionIn our cohort, one‐fourth of patients discontinued CT‐P13 during 6 months of follow‐up, mainly due to an increase in the subjective features of the tender joint count and the patient's global assessment of disease activity and/or subjective AEs, possibly explained by nocebo effects and/or incorrect causal attribution effects.
Ixekizumab significantly improves symptoms of psoriatic arthritis in patients naive to prior biologic therapy and in patients who had failed prior to biologic therapy.FDA Approvals
Authors: Zabotti A, Idolazzi L, Batticciotto A, De Lucia O, Scirè CA, Tinazzi I, Iagnocco A Abstract Psoriatic arthritis is a systemic inflammatory disease in which enthesitis and dactylitis are two of the main hallmarks of the disease. In the last years, ultrasonography is increasingly playing a key role in the diagnosis of psoriatic arthritis and ultrasonography of the entheses, particularly of the lower limbs, is commonly used to assess patients with that disease. New advancements in ultrasound equipment using high frequencies probes allowed us also to identify and characterize the involvem...